MOR-106

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C) . MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis[1][2].

Product Specifications

CAS Number

[2304625-87-2]

Product Name Alternative

MOR12743; MOR03207

UNSPSC

12352203

Target

Interleukin Related; NF-κB

Related Pathways

Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

References & Citations

[1]Vandeghinste N, et al. Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. J Invest Dermatol. 2018 Jul;138 (7) :1555-1563. |[2]Lauffer F, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2020 Apr;34 (4) :800-809.